scholarly journals Transaminases and gamma glutamyl transpeptidase for detecting nonalcoholic steatohepatitis and fibrosis in nonalcoholic fatty liver disease

2016 ◽  
Vol 8 (1) ◽  
pp. 61
Author(s):  
Shahinul Alam ◽  
Utpal Das Gupta ◽  
Jahangir Kabir ◽  
Sheikh Mohammad Noor-E-Alam ◽  
Ziaur Rahman Chowdhury ◽  
...  

<p><strong>Background:</strong> Nonalcoholic steatohepatitis (NASH) and advanced fibrosis are the spectrum of nonalcoholic fatty liver disease (NAFLD) that may progress to cirrhosis.</p><p><strong>Objective:</strong> We aimed to determine the detecting capacity of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transpeptidase (GGT) for NASH and <br />significant fibrosis.</p><p><strong>Methods:</strong> Demographic and laboratory data of 502 sonologically diagnosed NAFLD patients were retrospectively analysed. Area under receiver operating characteristics curve (AUROC) was performed for NASH and fibrosis score ≥2 (significant fibrosis) with ALT, AST and GGT of 233 biopsied patients.</p><p><strong>Results:</strong> Of 502 patients ALT, AST and GGT was elevated in 252 (50.1 %), 184 (36.7%) and 138 (27.4%) respectively. There was no difference in histological activity and fibrosis score between normal and elevated ALT and AST. Forty two (40.2%) NASH and 23(20.2%) significant fibrosis had normal ALT level. GGT was differed in NASH and Non NASH (p&lt; .005) and between significant fibrosis (p&lt; .01) and insignificant fbrosis. To detect NASH AUROC curve ofGGT was 67.5%, whereas of ALT and AST was 55.2% and 55.7%. For significant fibrosis AUROC curve of ALT, AST and GGT was 44, 50 and 68.4 % respectively. GGT level of39.5 U/L could detect NASH with a 63% sensitivity and 65% specificity irrespective of sex. GGT 40.5U/L had 60% sensitivity and 59 % specificity to detect significant fibrosis. For fibrosis ≥2 AUROC curve was 75.4% in male.</p><p><strong>Conclusion:</strong> No optimal ALT and AST level could detect NASH and fibrosis. GGT level of 40 U/L had a better detecting capacity for NASH and fibrosis especially in male. </p>

2018 ◽  
Vol 39 (2) ◽  
pp. 332-341 ◽  
Author(s):  
Donghee Kim ◽  
Won Kim ◽  
Sae Kyung Joo ◽  
Jung Ho Kim ◽  
Stephen A. Harrison ◽  
...  

2014 ◽  
Vol 51 (3) ◽  
pp. 261-268 ◽  
Author(s):  
Stergios A POLYZOS ◽  
Panagiotis NIKOLOPOULOS ◽  
Angeliki STOGIANNI ◽  
Iordanis ROMIOPOULOS ◽  
Panagiotis KATSINELOS ◽  
...  

Context Limited clinical data suggest Helicobacter pylori (Hp) infection may contribute to nonalcoholic fatty liver disease (NAFLD) pathogenesis. Objectives The effect of Hp eradication on hepatic steatosis (magnetic resonance imaging), nonalcoholic fatty liver disease fibrosis score and HSENSI (Homocysteine, serum glutamic oxaloacetic transaminase, Erythrocyte sedimentation rate, nonalcoholic steatohepatitis Index) in nonalcoholic steatohepatitis patients. Methods Thirteen adult patients with biopsy-proven nonalcoholic steatohepatitis, asymptomatic for gastrointestinal disease, underwent 13C urea breath test; Hp positive patients received eradication therapy until repeat test become negative. Hepatic fat fraction, standard biochemical tests and calculation of nonalcoholic fatty liver disease fibrosis score and HSENSI were performed at baseline and month 12. Results Hepatic fat fraction was similar for between and within group comparisons. Nonalcoholic fatty liver disease fibrosis score showed a non-significant trend towards decrease in Hp(+) [-0.34 (-1.39-0.29) at baseline and -0.24 (-0.99-0.71) at month 12; P = 0.116], whereas increase in Hp(-) group [-0.38 (-1.72-0.11) and -0.56 (-1.43-0.46), respectively; P = 0.249]. HSENSI was significantly decreased only in Hp(+) group [1.0 (1.0-2.0) at baseline and 1.0 (0-1.0) at month 12; P = 0.048]. Conclusions Hp eradication had no long-term effect on hepatic steatosis, but showed a trend towards improvement in nonalcoholic fatty liver disease fibrosis score and HSENSI. These results warrant larger studies with paired biopsies.


2016 ◽  
Vol 67 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Michiie Sakamoto ◽  
Hanako Tsujikawa ◽  
Kathryn Effendi ◽  
Hidenori Ojima ◽  
Kenichi Harada ◽  
...  

Hepatology ◽  
2013 ◽  
Vol 59 (1) ◽  
pp. 121-129 ◽  
Author(s):  
An Verrijken ◽  
Sven Francque ◽  
Ilse Mertens ◽  
Janne Prawitt ◽  
Sandrine Caron ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document